Taigen Biopharmaceuticals Holdings Ltd

TaiGen Biopharmaceuticals Holdings Limited is a pharmaceutical company that develops novel therapeutics for transformative diseases worldwide. Its pipeline includes Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic in Phase II trials for community-acquired pneumonia and diabetic foot infection; TG-1000 in Phase III trials for influenza A and B; TG-4318; ISM-4808 for CKD anemia; Furaprevir, an HCV protease inhibitor for chronic hepatitis C; and Burixafor, a stem cell mobilizer in Phase II trials for stem cell transplantation and chemosensitization. The company also provides pharmaceutical technology consulting and manufactures and sells health food. Founded in 2001, it is based in Taipei City, Taiwan.